

## Denosumab (Prolia®)

DENOSUMAB is a fully human, highly specific, monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL). The antibody is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts; the cells responsible for bone resorption. Denosumab prevents RANKL from activating on its receptor, RANK, present on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. Ultimately, denosumab blocks osteoclast activation, thereby resulting in decreased bone resorption [less bone breakdown].

### Resources from Manufacturer

[Patient Medication Guide](#)

[Full Prescribing Information](#)

[Bone Matters](#)

[Financial Assistance](#)

[REMS Program](#)

### FDA-Approved Indications and Dosing in Rheumatology

#### Denosumab is indicated for:

- Treatment of postmenopausal women with osteoporosis at high risk for fracture
- Treatment to increase bone mass in men with osteoporosis at high risk for fracture
- Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

#### Subcutaneous Dosing

- Denosumab should be administered by a healthcare professional.
- For all indications: administer 60mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen.
- All patients should receive calcium 1000mg and at least 400 IU vitamin D daily.

## Contraindications

- Hypocalcemia
- Pregnancy
- Known hypersensitivity to denosumab

## Warnings and Precautions

1. Same Active Ingredient: Patients receiving Prolia® should not receive XGEVA®
2. Hypersensitivity including anaphylactic reactions may occur. Discontinue permanently if a clinically significant reaction occurs.
3. Hypocalcemia: Must be corrected before initiating denosumab. Hypocalcemia may worsen, especially in patients with renal impairment. Adequately supplement patients with calcium and vitamin D.
4. Serious infections including skin infections may occur, including severe infections requiring hospitalization. Advise patients to seek prompt medical attention, if they develop signs or symptoms of infection, including cellulitis.
5. Dermatitis, eczema and rashes may occur.
6. Pregnancy
7. Osteonecrosis of the jaw (ONJ) has been reported with denosumab – monitor for symptoms.
8. Atypical femoral fractures have been reported. Evaluate patients with thigh or groin pain for femoral fracture.
9. Severe bone, joint, muscle pain may occur. Discontinue use if severe symptoms develop.
10. Suppression of bone turnover: Significant suppression has been demonstrated. Monitor for consequences of bone over suppression.

## Adverse Reactions

- Postmenopausal osteoporosis: Most common adverse reactions (>5%) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain and cystitis. Pancreatitis has been reported in clinical trials.
- Male osteoporosis: Most common adverse reactions (>5%) were: back pain, arthralgia and nasopharyngitis.
- Bone loss due to hormone ablation for cancer: Most common adverse reactions (>10%) were: arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials.

## Medication Strength and Preparations

- Available single use prefilled syringe of 60mg/mL

## Medication Administration and Storage

- Injection should be stored under refrigeration between temp of 2 to 8° C

### Subcutaneous Administration

1. Prior to administration, denosumab may be allowed to reach room temperature in the original carton. This generally takes 15 to 30 minutes. Do not warm by any other method. Once removed from the refrigerator, denosumab must be maintained at room temperature [up to 77°F [25°C]] in the original carton and must be used within 14 days.
2. Visually inspect denosumab for particulate matter and discoloration prior to administration whenever solution and container permit. Denosumab is a clear, colorless to pale yellow solution that may contain trace amounts of translucent to white protein particles. Do not use if the solution is discolored or cloudy or if the solution contains many particles or foreign particulate matter.
3. Latex Allergy: People sensitive to latex should not handle the grey needle cap on the single-use pre-filled syringe, which contains dry natural rubber [a derivative of latex].
4. In order to minimize accidental needle sticks, the denosumab (Prolia®) single-use prefilled syringe has a green safety guard that may be activated after the injection is administered.
5. Remove gray needle cap and inject subcutaneously into abdomen (avoiding 2-inch area around navel), upper arm or thigh
6. Insert needle and inject all liquid subcutaneously, hold prefilled syringe by clear finger grip with one hand, with other hand gently grasp and slide green safety guard toward the needle until you hear a click
7. Do not slide the safety guard forward over the needle before administering the injection—it will lock in place and prevent injection.
8. Immediately dispose of needle into sharps container

## Pre-Administration Checklist and Screening

1. Calcium levels should be assessed prior to administration of denosumab. Hypocalcemia must be corrected prior to initiating therapy with denosumab.
2. Patient cannot have any signs and symptoms of infection. Ensure patient is not on an antibiotic.
3. May want repeat calcium level after injection in high risk populations.

### Updated June 2023—ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is published by the American College of Rheumatology (“ACR”) for informational purposes only, in furtherance of its educational mission. It is not a substitute for user’s independent medical discretion or decision making, nor a replacement for the manufacturer’s complete prescribing and labeling information, as in effect at the time of use. The information contained herein reflects the conclusions of the individual companies who manufacture the products and not those of the ACR. ACR does not endorse or make any statement regarding the efficacy or safety of any of the listed companies or any of their drugs or other products. ACR specifically disclaims any and all responsibility or liability for the accuracy or completeness of the contents of this reference guide, the use of such information by anyone and/or for the performance of any of the drugs listed in this biologic reference guide [including without limitation, any adverse effects].